Hyderabad-based Hetero enters into agreement with MSD

Under this licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation.

Hyderabad: Hyderabad-based Hetero, a generic pharmaceutical company, entered into a non-exclusive voluntary licensing agreement with MSD for the manufacturing and distribution of investigational oral therapeutic antiviral drug Molnupiravir for the treatment of Covid-19.

Under this licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries (LMICs), following the approvals for emergency use authorisation by local regulatory agencies.

---

Molnupiravir is an investigational oral antiviral agent currently being studied in a phase 3 trial for the treatment of non-hospitalised patients with confirmed Covid-19. MSD is developing Molnupiravir in collaboration with Ridgeback Biotherapeutics.

Dr B Partha Saradhi Reddy, chairman, Hetero Group of Companies, said, “Hetero has partnered with MSD to enable access of Molnupiravir for Covid-19 to the Indian population at this much important time to fight the pandemic. We are vertically integrated to manufacture and commercially ready to supply this product to patients swiftly across the country.”

“We will be immediately approaching the DCGI to seek regulatory pathway and emergency use authorisation,” he added.

Molnupiravir will be manufactured in the company’s formulation facility in Hyderabad, which has been approved by regulatory authorities such as the USFDA and EU, among others.

Molnupiravir (EIDD-2801/MK-4482) is an investigational, orally bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of Covid-19. It has been shown to be active in several models of SARS-CoV-2, including for prophylaxis, treatment and prevention of transmission, as well as SARS-CoV-1 and MERS.

The drug candidate was invented at Drug Innovations at Emory (DRIVE), a not-for-profit biotechnology company, wholly owned by Emory University. Since licensed by Ridgeback, all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and MSD.

---

Now you can get handpicked stories from Telangana Today on Telegram everyday. Click the link to subscribe.

Click to follow Telangana Today Facebook page and Twitter .